Hovione files its first Investigational New Drug Application with the FDA

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic

Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction

Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel

Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.

Hovione Announces Enrollment of First Patient in MARS

A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel

Hovione Announces Start of Phase 1 Clinical Trial of HY02

HY02, a Proprietary Minocycline Sterile Ointment to Treat a Subset of Anterior Ocular Inflammation